Cambrex Corporation and Tillotts Pharma AG are announced that they have entered into a development and commercialization agreement for a proprietary mesalamine-based (5-ASA) technology for use in the treatment of Inflammatory Bowel Disease (IBD).
“This deal, which gives Tillotts worldwide access to an exciting proprietary 5-ASA-based technology, is an additional important step in our forceful efforts over the years to come to build an attractive and innovative gastrointestinal product portfolio, complementary to our Asacol and Colpermin,” commented Thomas A Toth von Kisker, president and CEO of Tillotts.
Steven M Klosk, president and CEO of Cambrex added, “Today's announcement serves as a prime example of Cambrex's commitment to accelerating our customers' drug development processes by providing technology-added products and services and further underscores our goal to being a leading player in the development and supply of mesalamine-based active ingredients.”
Under the terms of the agreement, Tillotts has acquired from Cambrex worldwide exclusive rights to develop and commercialize drug products based on the proprietary 5-ASA-based technology in exchange for developmental, regulatory and IP milestone payments as well as royalties. Cambrex previously acquired the exclusive rights to this technology from PLx Pharma Inc. (Houston, TX).
Tillotts is a speciality pharma company with a leading position in the field of gastroenterology with its headquarters in Rheinfelden, Switzerland. It specializes in the development and commercialization of pharmaceutical products, diagnostics as well as medical devices all in the field of gastroenterology.
Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics.